Wellbutrin XL Receives Seasonal Affective Disorder Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The GSK antidepressant is the first drug approved to treat seasonal affective disorder.
You may also be interested in...
Teva's Generic Wellbutrin XL For Major Depressive Disorder Launches
GSK has more than two years to market Wellbutrin XL in seasonal affective disorder before generics for that indication can launch.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications